- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.12. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies | 108 | GlobeNewswire (Europe) | PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative... ► Artikel lesen | |
| 01.12. | Cognition Therapeutics outlines Phase 3 plans for Alzheimer's drug | 3 | Investing.com | ||
| 13.11. | Cognition Therapeutics completes enrollment in Alzheimer's drug trial | 1 | Investing.com | ||
| 13.11. | Cognition Therapeutics, Inc.: Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease | 149 | GlobeNewswire (Europe) | PURCHASE, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders... ► Artikel lesen | |
| COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.11. | Cognition Therapeutics GAAP EPS of -$0.06 | 2 | Seeking Alpha | ||
| 06.11. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs | 169 | GlobeNewswire (Europe) | - $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine (CT1812) - - Aligned with U.S. FDA on Registrational Path for Zervimesine - - Expanded Access Program for... ► Artikel lesen | |
| 06.11. | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.11. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 15.09. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 4 | SEC Filings | ||
| 03.09. | Cognition Therapeutics, Inc.: Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target | 190 | GlobeNewswire (Europe) | PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders... ► Artikel lesen | |
| 02.09. | Cognition Therapeutics schließt registrierte Direktplatzierung über 30 Millionen US-Dollar ab | 2 | Investing.com Deutsch | ||
| 02.09. | Cognition Therapeutics closes $30 million registered direct offering | 2 | Investing.com | ||
| 02.09. | Cognition Therapeutics, Inc.: Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812) | 2 | GlobeNewswire (USA) | ||
| 28.08. | Cognition Therapeutics: Aktie bricht nach 30-Millionen-Dollar-Direktplatzierung ein | 1 | Investing.com Deutsch | ||
| 28.08. | Cognition Therapeutics stock falls after $30 million direct offering | 1 | Investing.com | ||
| 28.08. | Cognition Therapeutics launches $30M share offering | 2 | Seeking Alpha | ||
| 28.08. | Cognition Therapeutics, Inc.: Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock | 8 | GlobeNewswire (USA) | ||
| 26.08. | Cognition Therapeutics regains Nasdaq compliance on $1.00 bid price rule | 1 | Seeking Alpha | ||
| 26.08. | Cognition Therapeutics regains Nasdaq compliance with $1 share price | 2 | Investing.com | ||
| 26.08. | Cognition Therapeutics, Inc.: Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement | 191 | GlobeNewswire (Europe) | PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative... ► Artikel lesen |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,60 | +0,13 % | Erfreuliche Studiendaten verleihen der BioNTech-Aktie wieder Rückenwind, doch für einen Durchbruch reicht es noch nicht | Vor fünf Jahren dominierte die Aktie von BioNTech noch das Börsengeschehen, mittlerweile schafft das Papier es aber nur noch selten auf das Radar der Anleger. Das Geschäft mit Corona-Impfstoffen ist... ► Artikel lesen | |
| CUREVAC | 4,056 | -0,93 % | Morgen-Update: Curevac sorgt für Spannung - kommt bald die Entscheidung? | ||
| AMGEN | 276,60 | -0,52 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,470 | -1,81 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| BIOGEN | 144,70 | -0,86 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| MAINZ BIOMED | 1,010 | 0,00 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,460 | +0,21 % | 1 Bold Prediction for Viking Therapeutics in 2026 | ||
| INTELLIA THERAPEUTICS | 7,586 | -2,24 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 58,50 | +0,86 % | Tempus AI's Strategic Push to Expand Beyond Oncology | ||
| BIOCRYST PHARMACEUTICALS | 6,400 | +0,44 % | XFRA BO1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOCRYST PHARMAC.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 44,070 | 0,00 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 18,980 | 0,00 % | Sarepta rises as HHS adds Duchenne muscular dystrophy to newborn screenings | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,671 | -2,58 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| EXELIXIS | 34,920 | -1,38 % | Exelixis stock holds steady as Stifel maintains $43 price target | ||
| CARDIOL THERAPEUTICS | 0,857 | -1,61 % | Cardiol Therapeutics Inc.: New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions | Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with... ► Artikel lesen |
Das Unternehmen COGNITION THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,06 % bei einem Aktienkurs von 1,535 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COGNITION THERAPEUTICS INC finden Sie auf Wallstreet Online.